1. Scrip
  2. >>Business
  3. >>Strategy

CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year

Women’s Health Build-Up Continues Through Deals

 
• By Mandy Jackson

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

Three white checkmarks on multicolored toy circles in a row in the middle on bright aqua blue background
Ali highlighted progress across all three Organon businesses – established brands, biosimilars and women's health • Source: Shutterstock

Organon & Co. CEO Kevin Ali is the first to admit that the company faced a lot of skepticism when it spun out of Merck & Co., Inc. with three seemingly disparate sets of assets – established products, biosimilars and women’s health – with plans to most aggressively invest in women’s health for growth. Ali is also the first to note that the company has delivered on its promises across all three areas during its first year.

“Investors and analysts at the very beginning when we first spun out were wondering how these three pieces of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business